Aravive, Inc. (ARAV)

NASDAQ: ARAV · IEX Real-Time Price · USD
0.817
-0.058 (-6.61%)
Sep 30, 2022 4:00 PM EDT - Market closed
-6.61%
Market Cap 24.94M
Revenue (ttm) 6.10M
Net Income (ttm) -55.58M
Shares Out 30.52M
EPS (ttm) -2.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 105,752
Open 0.885
Previous Close 0.875
Day's Range 0.797 - 0.885
52-Week Range 0.580 - 4.250
Beta 2.42
Analysts Buy
Price Target 18.56 (+2,171.2%)
Earnings Date Oct 26, 2022

About ARAV

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a solub... [Read more...]

Industry Biotechnology
IPO Date Mar 21, 2014
CEO Gail McIntyre
Employees 23
Stock Exchange NASDAQ
Ticker Symbol ARAV
Full Company Profile

Financial Performance

In 2021, Aravive's revenue was $7.44 million, an increase of 30.91% compared to the previous year's $5.69 million. Losses were -$39.15 million, 28.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ARAV stock is "Buy." The 12-month stock price forecast is 18.56, which is an increase of 2,171.17% from the latest price.

Price Target
$18.56
(2,171.17% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference

HOUSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail M...

6 days ago - GlobeNewsWire

Aravive to Participate in H.C. Wainwright 24th Annual Global Investment Conference

HOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail M...

3 weeks ago - GlobeNewsWire

Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of 1.61% and 20.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) --  Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today report...

1 month ago - GlobeNewsWire

Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer

Dr. Geller is a Board-Certified Medical Oncologist with over 30 years of experience in the biopharmaceutical industry and academia Dr. Geller is a Board-Certified Medical Oncologist with over 30 years o...

2 months ago - GlobeNewsWire

Aravive Appoints Rudy Howard as Chief Financial Officer

HOUSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announc...

3 months ago - GlobeNewsWire

Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced o...

HOUSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announce...

4 months ago - GlobeNewsWire

Aravive to Participate in H.C. Wainwright Global Investment Conference

HOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIn...

4 months ago - GlobeNewsWire

Aravive (ARAV) Reports Q1 Loss, Tops Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of -16.98% and 2.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Aravive Announces Poster Presentations at the 2022 ASCO Annual Meeting

HOUSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the present...

5 months ago - GlobeNewsWire

Analysts Estimate Aravive (ARAV) to Report a Decline in Earnings: What to Look Out for

Aravive (ARAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

HOUSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that it has close...

6 months ago - GlobeNewsWire

Aravive (ARAV) Reports Q4 Loss, Misses Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of 3.12% and 36.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Aravive Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates

HOUSTON, March 31, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announ...

6 months ago - GlobeNewsWire

Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced today that it has...

6 months ago - GlobeNewsWire

Aravive to Participate In-Person at 34th Annual ROTH Conference

HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that Gail McIntyr...

6 months ago - GlobeNewsWire

Aravive Highlights Updated Batiraxcept Data From Kidney Cancer Trial

Aravive Inc (NASDAQ: ARAV) has announced new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell cancer (ccRCC). 26 previously treated ccRCC patients h...

6 months ago - Benzinga

Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting

HOUSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, will present updated exposu...

7 months ago - GlobeNewsWire

Is Aravive (ARAV) Stock Outpacing Its Medical Peers This Year?

Here is how Aravive (ARAV) and Cerner (CERN) have performed compared to their sector so far this year.

7 months ago - Zacks Investment Research

Aravive (ARAV) Upgraded to Buy: Here's Why

Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

7 months ago - Zacks Investment Research

Is Aravive (ARAV) Outperforming Other Medical Stocks This Year?

Here is how Aravive (ARAV) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

7 months ago - Zacks Investment Research

Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

Preliminary top line data anticipated throughout 2022 Preliminary top line data anticipated throughout 2022

8 months ago - GlobeNewsWire

Aravive Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Cha...

HOUSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that the comp...

8 months ago - GlobeNewsWire

Aravive to Participate in Fireside Chat at Piper Sandler 33rd Annual Virtual Healthcare Conference

HOUSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today annou...

10 months ago - GlobeNewsWire

Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with ...

3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline Batiraxcept has been generally well-tolerated with no dose-limiting toxicities Aravive ...

10 months ago - GlobeNewsWire